|Bid||135.58 x 30000|
|Ask||135.70 x 30000|
|Day's Range||137.22 - 140.78|
|52 Week Range||94.66 - 153.22|
|Beta (5Y Monthly)||0.26|
|PE Ratio (TTM)||22.73|
|Forward Dividend & Yield||2.74 (1.96%)|
|Ex-Dividend Date||May 14, 2020|
|1y Target Est||N/A|
Junshi Biosciences Co Ltd said on Tuesday that it is gearing up to initiate clinical trials to test its experimental COVID-19 antibodies together with Eli Lilly & Co (LLY), in the U.S. and China by the second quarter of the year.Eli Lilly, earlier this month announced its partnership with Junshi Biosciences, a China-based biopharmaceutical company specializing in the discovery and development of novel therapies. Since the coronavirus outbreak, Junshi Biosciences has created multiple neutralizing antibodies to combat COVID-19.Junshi Biosciences also published in the science journal Nature, efficacy data results from preclinical studies that tested two of the experimental monoclonal antibodies, CA1 and CB6, in rhesus monkeys. The results showed that while both antibodies demonstrated “substantial” neutralization activity in vitro against SARS-CoV-2, CB6 exhibited “superior” neutralizing activities.“The fact that CB6 can protect rhesus monkeys from COVID-19 infection suggests a potential for prophylactic use in humans,” said Daniel Skovronsky, Lilly’s chief scientific officer and president of Lilly Research Laboratories. “We are moving as quickly as possible to test such a protective effect in patients at risk for COVID-19.”As part of the collaboration, Lilly will receive an exclusive license to conduct clinical development, manufacturing and distribution of products outside of Greater China. Junshi Biosciences will maintain all rights in Greater China.Shares in Eli Lilly have been on a winning streak since March 23, advancing 24% to $147.56 as of early U.S. trading on Tuesday.Wall Street analysts are cautiously optimistic about Lilly’s stock outlook divided evenly between 4 Buy ratings and 4 Hold ratings, which add up to a Moderate Buy consensus. The $163.25 average price target implies 11% upside potential of 5.2% in the coming 12 months. (See Eli Lilly’s stock analysis on TipRanks).Related News: Merck Joins Race For Covid-19 Vaccine; Shares Rise 4.4% In Pre-Market Trading Novavax Begins Human Testing For Covid-19 Vaccine, Expects Results In July Gilead’s Remdesivir Most ‘Beneficial’ In Covid-19 Patients Who Need Extra Oxygen, Study Shows More recent articles from Smarter Analyst: * Macy’s Spikes 17% On Refinancing Plan To Weather Coronavirus Crisis * Redfin Brings Back Employees as Housing Market Heats Up * Merck Joins Race For Covid-19 Vaccine; Shares Rise 4.4% In Pre-Market Trading * Texas Capital CEO Resigns As Independent Bank Merger Terminated; Analyst Downgrades Stock
Lilly and several other drugmakers such as Gilead Sciences, Pfizer Inc and Merck & Co Inc are racing to develop treatments or vaccines for the fast-spreading respiratory illness caused by the novel coronavirus. Junshi said the companies intend to file an application to begin human testing of one of their two antibodies - protective proteins produced in response to infection - tested first in rhesus monkeys. Shanghai Junshi said results from the preclinical studies, published in the science journal Nature, show that both the tested antibodies, called CA1 and CB6, showed substantial neutralization activity against the virus.
Veeva Systems' (VEEV) fiscal first-quarter results are likely to reflect solid show by its segments and robust product portfolio.
President Donald J. Trump and Seema Verma, Administrator for the Centers for Medicare & Medicaid Services, today announced details of the new Part D Senior Savings Model that will allow people in the Medicare Part D program to buy their monthly prescription of insulin for no more than $35 starting January 1, 2021. David A. Ricks, Eli Lilly and Company (NYSE: LLY) Chairman and CEO, attended the announcement at the White House. Below is his statement about the Part D Senior Savings Model:
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced an academic research collaboration with the Duke Clinical Research Institute (DCRI) on a new trial, EMPACT-MI (EMPAgliflozin for the prevention of Chronic heart failure and morTality after an acute Myocardial Infarction). The collaboration will investigate whether Jardiance® (empagliflozin) can improve outcomes and prevent heart failure in adults with and without diabetes who have had an acute myocardial infarction, more commonly known as a heart attack. This randomized clinical trial will be conducted, analyzed and reported in partnership with the DCRI, with Boehringer Ingelheim and Lilly providing funding.
Emgality® (galcanezumab-gnlm) significantly improved work productivity and reduced interictal burden, defined as health and well-being between migraine attacks, in an analysis of the 3-month double-blind period of the CONQUER study, which included patients with migraine from 12 different countries. The Phase 3 CONQUER study evaluated the efficacy and safety of Emgality for the preventive treatment of episodic and chronic migraine in patients with documented previous treatment failures on two to four different standard-of-care migraine preventive medication categories, due to inadequate efficacy or for safety/tolerability reasons.
Medtronic (MDT) demonstrates weak fiscal fourth-quarter performances at CER, attributable to dismal show in all major business segments and geographies.
When it comes to investing in dividend stocks, it's patience that results in the real payday for shareholders.The most obvious measure of a company's income potential, its dividend yield, is calculated on an annualized basis using 12 months of distributions. That typically is spread across four payments, with one dividend paid out each quarter, meaning you can hold a stock for about 12 weeks without seeing a penny in dividends if you wind up selling at an inopportune time.Beyond the simple practicalities of making sure you're eligible for the next dividend, the real reason patience pays for income investors is the dramatic lift dividends provide over the very long term. Consider that the S&P; 500 Index of large U.S. stocks is up 167% since the beginning of 2010. However, if you account for the dividends paid out by the constituent stocks in this benchmark and reinvest that cash back into the index, your return jumps to more than 230% over the past 10 years or so!If this is the performance that dividends can deliver across a decade, imagine what happens when you account for a century or more of payouts.These 13 dividend stocks have provided just that: a rich history of uninterrupted cash distributions to shareholders stretching back at least 100 years. SEE ALSO: 25 Dividend Stocks the Analysts Love the Most
Is (LLY) Outperforming Other Medical Stocks This Year?
(Bloomberg) -- The air has suddenly come out of a rally in a biotech firm that’s been working with China’s military to develop a coronavirus vaccine.CanSino Biologics Inc. tumbled as much as 23% in Hong Kong trading on Thursday afternoon, erasing an earlier 16% surge. The stock had almost tripled since announcing on March 4 it was in the process of developing a vaccine. The rally accelerated after the company said on Monday Canada approved its clinical trial application for a vaccine.The sudden reversal underscores the risks in chasing the most popular theme this year -- vaccine producers. Moderna Inc. slumped from a record in New York trading earlier in the week as investors digested early data from a small trial of the company’s coronavirus vaccine, as well as a $1.3 billion stock sale.Some traders said a series of large transactions may have triggered the selloff in CanSino, with at least 17 trades comprising more than 10,000 shares each changing hands in the afternoon. Eli Lilly & Co. is the company’s biggest shareholder with a 15.5% stake, according to an April filing.The firm listed in Hong Kong in March last year, raising $160 million in a heavily oversubscribed initial public offering. It developed the first Ebola vaccine approved in China for emergency use and national stockpile, it said at at the time. The company has a current market value of $6.1 billion.CanSino made no revenue in 2019, according to a March exchange filing. Its operating loss was about 200 million yuan ($28 million) last year.Other biotech firms have rallied in Hong Kong as the coronavirus spread across the globe. Viva Biotech Holdings has jumped 65% this month, while Shanghai Junshi Biosciences Co. has surged to a record. Innovent Biologics Inc. slumped nearly 10% on Thursday after jumping almost 80% since mid-March.CanSino didn’t immediately reply to emails sent to its investor relations and press departments seeking comment on the stock move. An external representative said she couldn’t immediately comment on behalf of the company.“No one knows how much CanSino is worth,” Castor Pang, head of research at Core Pacific-Yamaichi International Hong Kong, said before the afternoon plunge. “People are making bets on the success of its vaccine, but the trial is just in stage two and there is possibility for it to fail.”CanSino shares were last down 14%, ending a 10-day winning streak. Its 14-day relative strength reached 89 on Thursday morning before the rally reversed. More than 70 indicates sentiment is overheated on a stock.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
McKesson's (MCK) fiscal fourth-quarter 2020 results benefit from strong segmental performance.
J&J (JNJ) faces thousands of lawsuits, which claim that its talc-based products, primarily its baby powders, cause cancer.
The FDA assigns a Breakthrough Therapy status to AstraZeneca's (AZN) Enhertu for treating patients with metastatic NSCLC whose tumors have a HER2 mutation.
Eli Lilly and Company (NYSE: LLY) announced baseline results from the GERAS-US Study examining the societal costs associated with mild cognitive impairment (MCI), mild dementia (MILD), and caring for someone with Alzheimer's disease (AD). The study, published today in The Journal of Alzheimer's Disease, is the first of its kind to show how early stages of cognitive decline economically impact both patients and caregivers. Alzheimer's is a relentless, fatal disease creating a health crisis for patients, families and society. Out of the top six diseases affecting Americans, AD is the only one with no treatment to prevent, cure or slow the disease.
Investors who are looking for good dividend stocks don't have to forgo the possibility of earning capital appreciation along the way. While many dividend stocks may sometimes offer mediocre returns, some have real potential. Eli Lilly (NYSE: LLY) is up 20% since the start of 2020, as the drug manufacturer's been a stable buy during a very volatile year thus far.
These two diabetes companies have been beating the market all year long, but that’s not the only reason you should consider investing in them.
Gilead Sciences Inc's two clinical studies of its potential coronavirus treatment remdesivir will wind down by the end of May, closing off a path of patient access to the antiviral medication, according to U.S. researchers involved in the studies. The drug was given emergency use authorization by the U.S. Food and Drug Administration on May 1, but hospitals are concerned about access. "We would like to see equitable and transparent distribution of this very precious resource," Dr. Helen Boucher, chief of infectious diseases at Tufts Medical Center in Boston, told Reuters.
Zacks.com featured highlights include: Clorox, Sprouts Farmers, Eli Lilly, Gold Fields and AngloGold
FDA approves Lilly's (LLY) selpercatinib for RET-altered lung and thyroid cancers and AstraZeneca (AZN)/Merck's (MRK) Lynparza for new ovarian cancer use.
STERIS' (STE) fourth-quarter fiscal 2020 results reflect strong segmental performance despite the coronavirus-led economic crisis.